公开(公告)号：US20170198005A1

公开(公告)日：2017-07-13

申请号：US15038925

申请日：2014-11-26

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： Jean-Laurent Paparin ,  Eric Badaroux ,  Claire Pierra ,  Cyril B. Dousson

IPC: C07H19/16 ,  A61K31/7068 ,  A61K45/06 ,  C07H19/10 ,  A61K31/7076 ,  A61K31/708 ,  C07H19/06 ,  A61K31/7072

CPC classification number: C07H19/16 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K45/06 ,  C07D405/04 ,  C07D473/18 ,  C07D473/40 ,  C07F9/65586 ,  C07F9/65616 ,  C07F9/65744 ,  C07H19/06 ,  C07H19/10 ,  C07H19/11 ,  C07H19/20

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2′-dichloro or 2′-fluoro-2′-chloro nucleoside analogue compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula (I): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; wherein each of RA and RB is independently Cl or F, wherein at least one of RA and RB is Cl; and Base, PD and Z are as described herein.